| CAS ID: | 1009119-64-5 |
| Molecular Formula: | C40H50N8O6 |
| Molecular Weight: | 738.9 g/mol |
| Monoisotopic Mass: | 738.3853 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | BMS-790052-05 | DACLATASVIR DIHYDROCHLORIDE | DAKLINZA | DACLATASVIR | BMS-790052 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1 | See All |
| InChI Key: | FKRSSPOQAMALKA-CUPIEXAXSA-N | |
| Smiles: | COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT02865369 | Disease | Liver fibrosis |
| Phase | Status | Not yet recruiting | |
| First Received | August 12, 2016 | Last Verified | March 7, 2017 |
| Sponsor | Sang Gyune Kim | ||
Trial Record 2
| ClinicalTrial ID | NCT02319031 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 18, 2014 | Last Verified | January 27, 2017 |
| Sponsor | Bristol-Myers Squibb | ||
Trial Record 3
| ClinicalTrial ID | NCT02596880 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 4, 2015 | Last Verified | October 18, 2016 |
| Sponsor | Tehran University of Medical Sciences | ||
Trial Record 4
| ClinicalTrial ID | NCT01888900 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | June 28, 2013 | Last Verified | February 7, 2017 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ||
Trial Record 5
| ClinicalTrial ID | NCT02349048 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | January 28, 2015 | Last Verified | March 1, 2017 |
| Sponsor | Janssen Research & Development, LLC | ||
| PubChem: | 25154714 |
| ChEMBL: | CHEMBL2023898 |